Buy Marbocyl 10% Indicated in the treatment of respiratory infections caused by susceptible strains of organisms. It is also indicated in the treatment of acute E. coli mastitis. Buy Marbocyl 10%
In pigs:Buy Marbocyl 10%
Indicated in the treatment of Metritis Mastitis Agalactia syndrome caused by susceptible strains of organisms. Buy Marbocyl 10%
Solution for Injection. Each 100ml contains marbofloxacin 10g, monothioglycerol 0.1g, metacresol 0.2g and disodium edetate 0.01g.
In cattle: Indicated in the treatment of respiratory infections caused by susceptible strains of organisms. It is also indicated in the treatment of acute E.coli mastitis.
The recommended dose rate is 1ml/50kg/day in a single daily injection by intramuscular, subcutaneous or intravenous routes in cattle and by intramuscular route in pigs.
Treatment durations are 3 days in pigs and 3 to 5 days in cattle.
In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.
Indications of Marbocyl 10% 100ml.
Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.
General precautions: No severe side-effects are to be expected at doses up to 3 or 5 times the recommended dose in cattle and pigs respectively. In particular, no lesions of the articular joints are encountered.
Intramuscular or subcutaneous injections are well tolerated although transitory inflammatory lesions without clinical impact can occur at the injection site.
May be used in pregnant and lactating cows and sows.
Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.
Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevelance of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.